Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 4NET 3CNS 2Head & Neck 1Gastrointestinal 1

Conditions

Pituitary Neoplasms 1Pheochromocytoma 1Parathyroid Neoplasms 1Paraganglioma 1Carcinoma, Medullary 1

Interventions

Cisplatin 21pembrolizumab 12Cetuximab 12Radiotherapy 11Carboplatin 10Nivolumab 9Radiotherapy, Intensity-Modulated 8Fluorouracil 8durvalumab 5Standard of Care 5epacadostat 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Drug Therapy 4Cyclophosphamide 4X-Rays 3Radiosurgery 3Radiation 3Practice Guidelines as Topic 3Panitumumab 3Gene Expression Profiling 3Docetaxel 3Biopsy 3fluoromisonidazole 2fludarabine 2cemiplimab 2aldesleukin 2Venlafaxine Hydrochloride 2Thyroxine 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × lutetium Lu 177 dotatate × Head & Neck × Clear all
NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡